Resmed, (ASX:RMD)’s shares plummet around 11% to A$30.130, marking its worst single day performance since January 2019.

The company is also set up for the most significant weekly loss since August 2020.

The medical equipment manufacturer reported a drop in its Q4 gross margin attributed to an unfavorable product mix combined with higher component and manufacturing costs.

As Citi points out, these lower margins resulted in an adjusted EPS of 160 cents, falling short of the Visible Alpha consensus of 168 cents.

Nevertheless, revenues increased by 23%, driven by demand for sleep and respiratory care devices.

Jefferies states that the Q4 results were slightly below consensus estimates, and as a result, decided to lower the price target to $240.00 from the initial $252.00.

The trading volume of the company’s shares is almost six times the 30-day average, marking its busiest trading day since March 2019.

Resmed, (ASX:RMD) is a leading manufacturer of medical equipment and devices, specializing in sleep and respiratory care products.

Shares of Mesoblast (ASX:MSB) tanked as much as 58.3% down to A$0.455, preparing for the worst trading session ever observed in the company, if the current trends persist.

The plummet came after the U.S.

FDA declined the company’s developed cell therapy intended for children under 12 years.

The therapy focused on treating a type of complication that often arises in the aftermath of stem cell or bone marrow transplant.

Mesoblast mentioned that the health regulator requested additional data to justify the marketing approval of the lead product remestemcel-L.

The company had appealed to the FDA for an approval of a cell therapy purposed to treat children disparaged by a type of graft versus host disease (GvHD), whose symptoms either did not respond to standard steroid therapy or recurred while continuing treatment.

With this news, the value of Mesoblast’s shares fell to their lowest since August 10, 2005.

Despite this setback, Mesoblast previously topped the losses on the ASX All Ordinaries index and saw over 52.5 million shares change hands compared to the usual 30-day average volume of approximately 2.7 million shares.

Up until the latest closing, the shares of Mesoblast were up by 25.3% Year-To-Date.

Mesoblast is a biopharma company that specializes in developing innovative cellular medicines to treat serious and life-threatening inflammatory ailments.

Bendigo and Adelaide Bank (ASX:BEN) shares decline approximately 1.8% to A$9.130, marking lowest record since July 17.

The Australian bank discloses the impairment of certain software intangible assets and additional non-cash restructuring costs.

Indeed, these modifications will trigger a non-cash expense of A$60.8 million post tax, impacting its FY23 profit.

As a result, Bendigo and Adelaide Bank (ASX:BEN) is anticipated to face loss for the third consecutive session, if current trend maintains.

Earlier this year, the bank’s stock has dropped 6.6% contrasted to a 0.6% rise in the ASX 200 Financials index.

Bendigo and Adelaide Bank is a prominent banking and financial service provider in Australia.

Current predictions from Morgan Stanley suggest a mid-single-digit margin decline for Australian banks in the June quarter.

It is also expected that bank expenses will be largely in line with the bank’s near-term forecasts.

However, they anticipate that financial year 2024 and 2025 expense growth forecasts may need to be adjusted upwards due to recent multi-year wage agreements and escalating IT service costs.

The firm maintains that credit quality will hold steady, but predicts that the major banks' average loss rate will experience a mild increase around 2 basis points quarter-over-quarter in the June quarter.

Morgan Stanley predicts that Commonwealth Bank (ASX:CBA) will post a satisfactory second half 2023 result and announce an additional buyback of around one billion Australian dollars, but their future commentary will be the most significant influence on the share price.

The risk of another unsatisfactory margin result has also been raised for National Australia Bank (ASX:NAB).

The second half 2023 earnings for Bendigo and Adelaide Bank (ASX:BEN) are projected to meet or exceed consensus.

However, recent deposit pricing trends suggest a degree of caution is needed when looking forward to the 2024 fiscal year.

As for year-to-date stock performance, CBA has risen 0.1%, while NAB and BEN have slid 7.1% and 6.6% respectively.

Commonwealth Bank is a leading Australian bank, National Australia Bank is one of the four largest financial institutions in Australia, and Bendigo and Adelaide Bank is a retail bank serving around 1.5 million customers across Australia.

Shares of Block Inc (ASX:SQ2) experienced a plunge as high as 11.4% to A$103.00, recording their largest intraday percentage drop since March 24.

The stock of Block Inc (ASX:SQ2) reached its lowest point since July 11.

The digital payments company, led by Jack Dorsey, reported that July’s growth in gross profit stands at 21% compared to 27% in Q2.

The company also recorded Q2 net losses attributable to a total of $122.5 million, an improvement from the $208 million loss in the previous year.

In an earnings call, Chairman Jack Dorsey emphasized the company’s commitment to cost-cutting measures, outlined by a hiring slowdown strategy and revising share-based compensation.

As of the last close, the shares of Block Inc (ASX:SQ2) listed on the ASX have risen 26.5% year-to-date.

Block Inc is a digital payments company led by Jack Dorsey.

Australian share registry firm Link Administration’s (ASX:LNK) stock has fallen 0.3% to A$1.45, marking a decline for the fourth consecutive day.

Analysts at Citi have also lowered their price target for the firm from A$1.60 to A$1.50.

According to the brokerage, several small acquisitions have boosted LNK’s income and operating EBIT for FY23.

However, the firm raised concerns about enduring uncertainties, thus maintaining their ‘neutral’ rating.

Recently, Link Administration warned of a projected FY23 statutory loss after tax of about A$417.7 mln, a significant jump from last year’s A$67.6 mln loss.

The firm attributes this expected loss to the necessary provisions broadly tied to a financial examination into its Fund Solutions business, as well as one-off costs associated with its recent sale.

Among seven analysts, two rate Link Administration as a ‘buy’ or higher, four suggest to ‘hold’, and one recommends a ‘sell’, with the median price target being A$2.03 according to Refinitiv data.

To date, the company’s shares have dropped 26.3% this year, contrasting with a 3.9% rise in the ASX 200 benchmark index.

Link Administration is an Australia-based firm that primarily provides share registry services.

Resmed (ASX:RMD) shares are in a slump, dropping as much as 14% to A$30.69, threatening their worst performance day since March 23, 2020, if the losses persist.

The medical equipment manufacturing company announced a decrease in its quarterly gross margin, brought on by an unfavourable product mix and increasing component and manufacturing costs.

This contraction in gross margin led to adjusted earnings per share settling at 160 cents, which is 5% lower than Visible Alpha consensus of 168 cents, as stated by Citi.

Despite this, Resmed posted a 23% increase in revenue up to $1.1 billion, thanks to rising demand for their sleep and respiratory care devices.

There’s considerable action in terms of share movements as approximately 7.1 million shares have been traded, which is 5.8 times the 30-day average volume of about 1.2 million shares.

The shares hit their lowest in more than a year.

Yet, the Resmed stock has seen an approximately 9.3% rise this year, as of the last closing.

Resmed is a medical equipment manufacturing company specializing in sleep and respiratory care devices.

Macquarie analysts recently lowered their price target on Argosy Minerals (ASX:AGY) from A$0.80 to A$0.75 while retaining an ‘outperform’ rating.

The brokerage stated that the revised price target reflects increased equity dilution in its funding assumption for Argosy Minerals (ASX:AGY)’s Rincon project, which is a response to the decrease in the company’s share price.

Argosy Minerals, a lithium exploration company, reported last Thursday that pumping tests at its Rincon lithium project confirm its economic viability in extracting brine from the deep sand aquifer.

Macquarie suggested that the economics of extracting brine from the black sand aquifer could potentially better than initially anticipated.

The stock of Argosy Minerals (ASX:AGY) was trading 5.9% lower.

According to Refinitiv data, two analysts rate the stock as ‘buy’ or higher, with a median price target of A$0.80.

So far this year, the stock is down 40.4%.

Argosy Minerals (ASX:AGY) is a lithium exploration company primarily focusing on the Rincon lithium project.

Shares for EV Resources (ASX:EVR) have experienced a significant boost, jumping as tremendously as 21.4% to stand at a notable A$0.017 - the highest value since May 18.

This rise comes on the heels of the Australian metals mining company announcing the completion of agreements for the purchase of a 70% stake in the high-grade Parag copper-molybdenum project located in Peru.

It’s also worth mentioning that permitting and planning activities for an initial 8km diamond hole programme are already underway.

EV Resources (ASX:EVR) witnessed its highest intraday percentage gains since May 4, although the stock’s overall performance has been flat this year, up until the most recent close.

EV Resources is an Australian mining company specializing in the exploration and extraction of metal resources.

Shares of Suncorp (ASX:SUN) dropped as much as 3.4% to A$13.56, on track to chalk up the biggest loss since March 20, should the current trend persist.

This comes as Australia’s competition regulator effectively roadblocked the planned $3.2 billion takeover of Suncorp’s banking division by ANZ Group (ASX:ANZ), indicating that the acquisition could potentially hamper competition within the sector.

Suncorp and ANZ have jointly stated they will seek a review of the decision from the Australian Competition Tribunal, a division of the federal court in charge of overseeing such rulings.

Analysts at Citi have speculated that the ANZ-Suncorp could have a better chance of passing muster with the Australian Competition Tribunal, albeit the conclusion might be delayed for another 6-9 months to approximately mid-2024.

The current verdict from ACCC is predicted to postpone any plans Suncorp might have had for a capital return.

Suncorp’s share price hit its lowest mark since March 20 and is down 2% so far this week, after three consecutive weeks of gains.

ANZ, on the other hand, saw a rise of up to 1.6% to A$25.67 on Friday.

As of the last closing, Suncorp’s shares have increased by 16.6% this year.

Suncorp (ASX:SUN) is a leading insurance, banking, and wealth management company based in Australia.